FARMACIA HOSPITALARIA最新文献

{"title":"[Translated article] Making research accessible, breaking down barriers: the new frontier of clinical trials","authors":"José Luis Revuelta-Herrero , Fernando Bustelo-Paz , Vicente Escudero-Vilaplana , Ana Herranz-Alonso","doi":"10.1016/j.farma.2026.02.001","DOIUrl":"10.1016/j.farma.2026.02.001","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages T141-T143"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147311204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Management of analgosedation and delirium in the critically ill patient","authors":"María Martín Cerezuela ,&nbsp;Esther Domingo Chiva ,&nbsp;Tatiana Betancor García ,&nbsp;Miguel Ángel Amor García ,&nbsp;Irene Aquerreta González ,&nbsp;Marta Albanell-Fernández ,&nbsp;Laura Doménech Moral ,&nbsp;Carla Bastida Fernández ,&nbsp;Sara Ortiz Pérez ,&nbsp;Sara Cobo Sacristán ,&nbsp;Aurora Fernández Polo ,&nbsp;Amaia Egüés Lugea ,&nbsp;Fernando Becerril Moreno","doi":"10.1016/j.farma.2025.12.006","DOIUrl":"10.1016/j.farma.2025.12.006","url":null,"abstract":"<div><div>The management of pain, agitation/sedation and delirium is a fundamental part of the treatment received by patients admitted to Intensive Care Units (ICU). The use of different strategies for the prevention and treatment of pain, agitation and delirium is one of the bases in the management of these patients. Knowledge of the different techniques for monitoring pain and delirium, pharmacokinetic behavior and the dosage used in this population, as well as the adverse effects and their management, is essential in order to provide optimal pharmacotherapeutic validation by the ICU clinical pharmacist.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages T167-T173"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Multidisciplinary approach to prenatal cystic fibrosis with cystic fibrosis transmembrane regulator modulators: Experience in a clinical case","authors":"Pedro del Palacio-García ,&nbsp;Carmen García-Muñoz ,&nbsp;María Dolores Canales-Siguero ,&nbsp;Maria Carmen Luna-Paredes ,&nbsp;Enrique Salcedo-Lobato ,&nbsp;Fernando Huecas-Jiménez ,&nbsp;Carlota Esperanza Vaquer-Ferrer ,&nbsp;José Miguel Ferrari-Piquero","doi":"10.1016/j.farma.2025.09.005","DOIUrl":"10.1016/j.farma.2025.09.005","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages T204-T207"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relación entre concentraciones plasmáticas de ustekinumab en la semana 8 y su efectividad en pacientes con enfermedad de Crohn","authors":"Betel del Rosario García ,&nbsp;Laura Ramos ,&nbsp;Ruth Ramos Díaz ,&nbsp;Ana Salas Pérez ,&nbsp;Marta Carrillo Palau ,&nbsp;Cristina Reygosa Castro ,&nbsp;Inmaculada Alonso Abreu ,&nbsp;Sergio Medina Chico ,&nbsp;Fernando Gutiérrez Nicolás","doi":"10.1016/j.farma.2025.11.007","DOIUrl":"10.1016/j.farma.2025.11.007","url":null,"abstract":"<div><h3>Objective</h3><div>The individualization of treatments through pharmacokinetic monitoring is a therapeutic strategy aimed at improving both the effectiveness and safety of drug therapy. For tumor necrosis factor inhibitors used in Crohn's disease, a robust correlation has been demonstrated between drug exposure and clinical response. However, evidence regarding ustekinumab concentrations and their relationship with treatment effectiveness remains limited.</div><div>The objective of this study was to analyze ustekinumab concentrations at week 8 of treatment for Crohn's disease and to evaluate their association with biochemical remission at week 24 and treatment persistence.</div></div><div><h3>Methods</h3><div>This prospective study included patients with Crohn's disease who initiated ustekinumab between 2020 and 2023. Ustekinumab trough plasma concentrations were measured at week 8. Quartile analysis and binary logistic regression were performed to assess the relationship between ustekinumab concentrations and biochemical remission rates at week 24. Treatment persistence across concentration quartiles was evaluated using Kaplan–Meier analysis.</div></div><div><h3>Results</h3><div>A total of 36 patients were included. Individuals achieving biochemical remission at week 24 had higher ustekinumab concentrations at week 8 compared with non-responders (10.64 vs. 5.83 μg/mL; <em>p</em> = 0.016). Patients within the quartile-4 (&gt;<!--> <!-->13.29 μg/mL) at week 8 showed significantly higher biochemical remission rates at week 24 compared with the remaining quartiles (100% vs. 57.1%; <em>p =</em> 0.023); Odds Ratio = 1.20; 95%-Confidence Interval [1.02–1.42]; <em>p =</em> 0.027. The 2-year treatment persistence rate was significantly greater among patients in quartiles 3–4 (100%) compared with those in quartile-1 (55.6%) and quartile 2 (50%) (<em>p =</em> 0.014).</div></div><div><h3>Conclusion</h3><div>This study confirms the association between ustekinumab concentrations at week 8 and treatment effectiveness in Crohn's disease. A concentration &gt;<!--> <!-->13.29 μg/mL at week 8 was identified as a predictive marker of biochemical remission at week 24, which could serve as a basis for future therapeutic decision-making algorithms.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages 151-157"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Alemtuzumab in relapsing–remitting multiple sclerosis in clinical practice: Annual NEDA-3 follow-up for up to 4 years","authors":"Leticia Herrero-Poch ,&nbsp;Maria Susana Fortes-González ,&nbsp;Antonio Pato-Pato ,&nbsp;Pablo Gaveiras-Araújo ,&nbsp;Martín Lorenzo-García ,&nbsp;Daniel Apolinar García-Estévez ,&nbsp;Jose Ramón Lorenzo-González","doi":"10.1016/j.farma.2025.12.005","DOIUrl":"10.1016/j.farma.2025.12.005","url":null,"abstract":"<div><h3>Objective</h3><div>The effectiveness of alemtuzumab in patients with relapsing–remitting multiple sclerosis (RRMS) have been demonstrated in clinical trials. The primary endpoint was to describe the annual effectiveness of alemtuzumab over a 4-year period, according to the different parameters of the NEDA-3 concept (no evidence of disease activity) in clinical practice.</div></div><div><h3>Methods</h3><div>A retrospective, observational multicentric open study of patients with RRMS treated with alemtuzumab between 2015 and 2024. Effectiveness was assessed according to different parameters of the NEDA-3 concept (absence of relapses, stability in disability status according to the EDSS scale, and absence of new lesions and/or contrast enhancement in brain magnetic resonance imaging) with annual follow-up for up to four years.</div></div><div><h3>Results</h3><div>A cohort of 32 patients (71.9% women, mean age 40.3 ± 11 years) were included. The proportion of patients achieving NEDA-3 was 51.7% (15/29) in the first year, 56.2% (12/26) in the second year, 47.4% (9/19) in the third year, and 47.1% (8/17) in the fourth year. At the end of the study, 82% of patients remained relapse-free, 59% had stable disability according to the EDSS scale, and over 47% were free of radiological activity.</div></div><div><h3>Conclusions</h3><div>Alemtuzumab has proven to be effective, over 4 years, in clinical practice in patients with RRMS according to the different parameters of the NEDA-3 concept.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages T158-T161"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146126704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Gender perspective in medication-related problems resulting in emergency department attendance involving high-alert medications.","authors":"Concepción Marín de la Bárcena, Jesús Ruiz Ramos, Mireia Puig Campmany, María José Otero, Ana Juanes Borrego","doi":"10.1016/j.farma.2026.03.005","DOIUrl":"https://doi.org/10.1016/j.farma.2026.03.005","url":null,"abstract":"<p><strong>Objectives: </strong>To characterize medication-related problems resulting in emergency department attendance involving high-alert medications, paying particular attention to sex-related differences in the type of the problem and medication associated with it.</p><p><strong>Methods: </strong>Retrospective observational study (2021-2022) based on the medical history at discharge, including adult patients seeking emergency department due to medication-related problems as a primary or secondary diagnosis. Patient grouping was performed according to the class of medication implicated in the event, as defined by the reference list of high-alert drugs for chronic patients (HAMC list). Sociodemographic and clinical baseline variables were collected. To explore gender differences in the type of problem and drug involved, statistical analysis included binomial tests and binary logistic regression with odds ratio estimation.</p><p><strong>Results: </strong>Among the 1,611 adult patients admitted to the emergency department with adverse events associated with a medication problem, 1,028 (64%) involved a high-alert medication. Women with moderate- and high-risk comorbidity showed a significative greater incidence of medication-related problems. Gender differences were particularly notable for events associated with loop diuretics (136 women [70%] vs 57 men [30%], p = 0.000); antipsychotics (30 women [65%] vs 16 men [35%], p = 0.039); opioids (37 women [73%] vs 11 men [27%], p = 0.000] and digoxin (22 women [81%] vs 5 men [19%], p = 0.02). Women showed a trend toward higher odds of experiencing unintentional drug poisoning (OR = 2.5; 95% CI: 0.786-8.356; p = 0.119). In contrast, non-adherence to prescribed high-alert medications occurred with greater frequency in men (OR = 0.711, 95% CI: 0.473-1.070; p = 0.102).</p><p><strong>Conclusions: </strong>A considerable proportion of medication-related problems that lead to emergency room attendance involve high-risk medications, and the type of problem presented and the type of drug involved differ between sexes. Findings highlight that addressing gender differences, especially with regard to high-risk medicines, could be crucial in moving toward safer and more equitable healthcare.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147822008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Possible severe gastrointestinal toxicity following the first cycle of mirvetuximab soravtansine in a patient with high-grade serous ovarian carcinoma.","authors":"Carlota Rodríguez-Tenreiro Rodríguez, Alicia Caso González, Marina Muñoz Villasur, Lucía Roncero Sánchez, Ana Lozano Blázquez","doi":"10.1016/j.farma.2026.03.008","DOIUrl":"https://doi.org/10.1016/j.farma.2026.03.008","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world evidence of immune-related adverse events as predictive factor of response in non-small cell lung cancer.","authors":"Maria Susana Fortes-Gonzalez, Silvia Vazquez-Blanco, Leticia Herrero-Poch, Lucia Santome-Couto, Ana Cristina Cercos-Lleti","doi":"10.1016/j.farma.2026.03.009","DOIUrl":"https://doi.org/10.1016/j.farma.2026.03.009","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to assess whether immune-related adverse events (irAE) act as predictive biomarkers of response to immune checkpoint inhibitors in non-small-cell lung cancer in real-life practice.</p><p><strong>Methods: </strong>Retrospective observational study in a third-level hospital.</p><p><strong>Inclusion criteria: </strong>adult patients with locally advanced or metastatic non-small-cell lung cancer treated with nivolumab, pembrolizumab or atezolizumab following platinum.</p><p><strong>Primary endpoint: </strong>association between ≥2 irAE and progression free survival (PFS) and overall survival (OS). Secondary endpoints: PFS, OS, overall response rate defined as the percentage of patients who achieve partial response or complete response, disease control rate and adverse events graded according to the Common Terminology Criteria for Adverse Events v5. Statistical analysis was performed using SPSS v23.</p><p><strong>Results: </strong>Fifty-seven patients treated with nivolumab (n = 25) pembrolizumab (n = 11) or atezolizumab (n = 21) were included. Median age was 62 (31-83) years and 81% had stage IV. Median PFS was 7.8 months (95% CI: 4.3-11.3) and OS was 13.4 months (95% CI: 5.8-20.9). Overall response rate and disease control rate were 28.1% and 59.6% respectively. irAEs occurred in 44% of patients, most frequently arthralgia, myalgia, and transaminase elevation. Grade 3 irAEs included: 3 cases of colitis, 2 pneumonitis, 1 hepatitis, 1 cutaneous toxicity, and 1 adrenal insufficiency. Survival was significantly longer in patients with ≥2 irAEs compared to those with <2: OS 28.4 vs 11.9 months (p = 0.025) and PFS 24.5 vs 5.2 months (p = 0.013).</p><p><strong>Conclusions: </strong>Patients experiencing 2 or more irAEs showed significantly improved survival, supporting the role of irAEs as potential biomarkers of response to immunotherapy in non-small-cell lung cancer.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacologic and pharmacokinetic factors in blood donation: A risk-based deferral framework proposal.","authors":"Roberto Lozano, María-Esther Franco, Carina Bona","doi":"10.1016/j.farma.2026.03.003","DOIUrl":"https://doi.org/10.1016/j.farma.2026.03.003","url":null,"abstract":"<p><strong>Objective: </strong>The presence of residual medications in blood donors can pose a risk to transfusion recipients, especially when drugs remain in plasma at clinically relevant levels. Current deferral recommendations for medicated donors are often generalized and lack pharmacokinetic rigor. This study aims to propose a pharmacologically and pharmacokinetically informed framework for assessing donor eligibility based on drug characteristics.</p><p><strong>Method: </strong>A structured literature review was conducted to evaluate key pharmacokinetic variables affecting drug persistence in blood, including half-life (t_½), time to maximum plasma concentration (t_max), maximum plasma concentration (C_max), and elimination pathways. Medications were stratified into five risk categories according to their pharmacological profile, systemic exposure, and clinical implications. Corresponding deferral periods were assigned to each category. The framework also considers the type of blood component being donated (e.g., plasma-rich vs. cellular products).</p><p><strong>Results: </strong>Medications with long half-lives, genotoxic effects, or antiplatelet activity pose higher transfusion risks and require extended deferral periods. Conversely, drugs with minimal systemic absorption, low plasma bioavailability, or that serve as physiological replacements pose minimal risk and may not warrant deferral. The proposed model aligns deferral recommendations with drug clearance data and product-specific plasma exposure.</p><p><strong>Conclusions: </strong>A pharmacokinetic approach to donor eligibility enhances transfusion safety and supports evidence-based deferral guidelines. Pharmacists and clinicians can collaborate to assess medication risk profiles and optimize donor selection. This model can reduce unnecessary deferrals and maintain blood supply integrity while protecting recipients.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real world outcomes of first-line pembrolizumab in metastatic non-small-cell lung cancer.","authors":"Amparo Burgos, Teresa Calleja, María Sacramento Díaz, Garbiñe Lizeaga, Cristina Ibáñez, Carmen María Valencia, Mónica Carbajales, David Conde, Juan Francisco Marín, Margarita Garrido, Raúl Díez, María José Martínez, María Larrosa, Estela Moreno","doi":"10.1016/j.farma.2026.02.015","DOIUrl":"https://doi.org/10.1016/j.farma.2026.02.015","url":null,"abstract":"<p><strong>Objective: </strong>To describe the effectiveness and safety of pembrolizumab in routine clinical practice as first-line treatment for advanced/metastatic non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50% and without EGFR or ALK alterations.</p><p><strong>Methods: </strong>Retrospective, multicenter observational study including patients diagnosed with advanced/metastatic NSCLC treated with pembrolizumab monotherapy as first-line therapy between January 2016 and July 2020. Clinical, treatment-related, and safety variables were collected. The primary effectiveness endpoints were overall survival (OS) and progression-free survival (PFS), estimated using the Kaplan-Meier method.</p><p><strong>Results: </strong>A total of 1005 patients from 42 Spanish hospitals were included, with a median age of 67 years (interquartile range [IQR]: 14); 256 were women. The predominant histology was non-squamous (725 patients). Median follow-up was 17.9 months (IQR: 24.1), and the median number of treatment cycles received was 8 (IQR: 21). Median PFS and OS were 8.7 months (95% confidence interval [CI]: 7.2-10.1) and 18.0 months (95% CI: 16.2-21.3), respectively. In the bivariate analysis, factors significantly associated with shorter OS included: age ≥ 75 years, body mass index (BMI) <25 kg/m², never smoking, performance status (PS-ECOG) ≥2, squamous histology, baseline liver or brain metastases, ≥2 metastatic sites at diagnóstico, Lung Immune Prognostic Index (LIPI) 1-2, and prior exposure to proton pump inhibitors (PPIs), corticosteroids, and antibiotics (within the previous 10 days). Overall, 61.7% of patients experienced some degree of toxicity (G1-5), and 15.3% had G ≥ 3 toxicities. Treatment discontinuation due to toxicity occurred in 115 patients (12.7%). Patients who developed toxicity had a median OS of 28.3 months (95% CI: 23.9-34.5), compared to 6.5 months (95% CI: 5.1-9.2) in those without toxicity (p < 0.0001).</p><p><strong>Conclusions: </strong>In advanced/metastatic NSCLC with PD-L1 ≥ 50% and no EGFR/ALK alterations, first-line pembrolizumab demonstrates outcomes consistent with the pivotal trial and with published real-world evidence. The findings confirm that PS-ECOG ≥2 and prior PPI exposure are predictors of shorter OS, and that the development of toxicity during treatment is significantly associated with longer survival.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}